Ligand Pharma (LGND) Gains After Retrophin (RTRX) Announces Positive Sparsentan Phase 2 Data
Find out which companies are about to raise their dividend well before the news hits the Street with StreetInsider.com's Dividend Insider Elite. Sign-up for a FREE trial here.
Retrophin previously secured a license to sparsentan from Ligand Pharmaceuticals and Bristol-Myers Squibb Company.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ligand Pharma (LGND) Announces Submission of Baxdela NDAs to FDA as ABSSSI Treatment
- Volatility and Volume movement
- 3M Co. (MMM) October weekly volatility increases to 33 into Q3 and outlook
Create E-mail Alert Related CategoriesTrader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!